SDS
20.10.2020 13:50:08 CEST | Business Wire | Press release
The Raiffeisen Banking Group and SDS announce the signing of a multi-year cooperation agreement. The Austrian Raiffeisen Banking Group is the country's largest banking group with the most intricate network of banks and around 2.8 million retail customers in Austria. Through Raiffeisen Bank International (RBI), the group is represented in 13 markets in Central and Eastern Europe. The Austrian company SDS (Software Daten Service) is one of the leading providers of modern banking technologies in securities processing tax and compliance automation, as well as associated services in Europe. Through its owner T-Systems International, it is part of Deutsche Telekom AG.
The two companies can look back at a long and successful cooperative history. Before SDS was taken over by T-Systems International in 2004, SDS, with its flagship product SDS GEOS, was owned by RZB (Raiffeisen Zentralbank) for 11 years, which itself took over the banking software provider from Schöllerbank in 1993. During this partnership of almost 30 years, the company developed one of the most competitive solutions for automated securities and derivative processing in Europe in the form of SDS GEOS. It also established a comprehensive portfolio of internationally successful support products for tax regulation or securities compliance and a software testing division that is strongly sought after in German-speaking countries, including companies outside the banking sector.
Through the specialised subsidiaries and associated companies of the Raiffeisen Banking Group, it is possible to meet the individual needs of each customer group and to provide an all-round financial service "under one roof". For example, RBI in Austria is specialised on commercial banking and investment banking business and advises the country's top 1,000 companies as a corporate finance bank and a bank for export financing. The all-round financial service of the Raiffeisen banking group also includes financial services of Raiffeisen specialist companies such as the investment company Raiffeisen Capital Management, Raiffeisen Versicherung, Raiffeisen-Leasing or Raiffeisen Bausparkasse.
The Raiffeisen Banking Group can count on a strong, reliable, and innovative technology partner not only because of its great international market success but also to ensure future competitiveness in light of the dynamic changes in international banking. These changes are driven by growing market and consumer digitalisation, the demand for and use of artificial intelligence, disruptive market participants, and the highest efficiency and response requirements, to mention only the most important of the current challenges.
SDS Managing Director Ernst Kendlbacher comments: "We are in the middle of a digital revolution in the banking sector. Innovations in terms of creating new processes and adapting to new technologies are essential for a healthy future. Raiffeisen will continue to purchase SDS products on a large scale in the future, thus further demonstrating its confidence in our portfolio. The new contract also includes all relevant security and regulatory requirements for the Raiffeisen group. A great success for both contract partners." Edzard Janssen, Head of Group Procurement, Outsourcing, and Cost Management of Raiffeisen Bank International AG adds: "In order to be sustainably successful in competition, it is important to work with professional and innovative partners."
View source version on businesswire.com: https://www.businesswire.com/news/home/20201020005678/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Zambon Announces European Commission Approval of Hopledo® for Adults with Parkinson's Disease and Moderate to Severe Motor Fluctuations28.8.2026 11:00:00 CEST | Press release
Hopledo® is a first-in-class, oral, modified-release formulation of levodopa/carbidopa (LD/CD) approved for the treatment of motor fluctuations of Parkinson’s disease Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026 The approval is based on data from the Phase 3 RISE-PD trial where Hopledo® demonstrated a significant increase in Good ON time compared with immediate-release LD/CD with fewer daily doses and a comparable safety profile Zambon today announced that the European Commission (EC) has granted marketing authorization for Hopledo® (modified-release levodopa/carbidopa) for the treatment of adult patients with Parkinson’s disease and moderate to severe motor fluctuations who have not been sufficiently stabilized with oral levodopa/dopa decarboxylase (DDC) inhibitor-based treatment regimens. Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026. The company is working closely
MTG-I2 Safely in Orbit, Unlocking Faster and Sharper Weather Monitoring Across Europe28.8.2026 10:16:00 CEST | Press release
The Meteosat Third Generation Imager 2 satellite (MTG-I2) has successfully passed its first critical post-launch milestones, completing the first full Meteosat Third Generation constellation in orbit. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828243790/en/ Credit: Arianespace livestream The imager satellite MTG-I2 is safely in orbit and operating as expected following its successful launch yesterday at 22:11 CEST on board an Ariane 6 rocket from Europe’s Spaceport in French Guiana. Our teams have established communication with the spacecraft, which has also deployed its solar panels to ensure its autonomous production of energy. MTG-I2 is in perfect shape to start its Launch and Early Operations Phase that will bring it to a higher orbit, 36 000km above Earth over the following two weeks, where a longer period of calibration and validation of its instruments will begin. This summer’s extreme weather and wildfires hav
New Daiichi Sankyo Data Underscore the Effect of Bempedoic Acid in the Real-World Management of Dyslipidemia and Cardiovascular risk28.8.2026 10:00:00 CEST | Press release
Analyses from the multinational MILOS study show that LDL-C reductions achieved with up to one year of treatment with bempedoic acid-containing therapies translate to a 17.1% relative reduction and a 4.8% absolute reduction in predicted 10-year cardiovascular risk.1 Real-world data demonstrated clinically relevant mean LDL-C reductions of at least 24.9%, regardless of patient gender or glycaemic status, after one year of follow-up.2,3 Findings presented at ESC Congress 2026 reinforce the clinical value of bempedoic acid in routine clinical practice, and demonstrate the continued investment of Daiichi Sankyo in addressing outstanding unmet needs in cardiovascular disease (CVD). Daiichi Sankyo (TSE:4568) today announced new results from the MILOS study that demonstrate the real-world impact of bempedoic acid administered either alone or as a fixed-dose combination with ezetimibe, in the management of dyslipidaemia. Presented at the European Society of Cardiology Congress 2026 in Munich,
TVS Motor Company Appoints Peyman Kargar as Director and Chief Executive Officer28.8.2026 09:31:00 CEST | Press release
Peyman Kargar appointed Director and Chief Executive Officer of TVS Motor Company, effective January 27, 2027 K. N. Radhakrishnan to continue as Director and Chief Executive Officer until then and subsequently will serve as Non-Executive Director up to the date of the ensuing AGM scheduled in July 2027 Appointment supports TVS Motor Company's next phase of growth and innovation TVS Motor Company, part of TVS VENU and a leading global manufacturer of two and three-wheelers, today announced the appointment of Peyman Kargar as Director and Chief Executive Officer, effective January 27, 2027. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260827012301/en/ Peyman Kargar Peyman will succeed K. N. Radhakrishnan, who will continue in his role until then to ensure a seamless transition. Following the transition, Radhakrishnan will serve as Non-Executive Director up to the date of the ensuing AGM scheduled in July 2027. He has been a
Philips and Imricor Launch Cardiac Interventional MR Lab Solution, Expanding Longstanding Collaboration27.8.2026 21:27:00 CEST | Press release
Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, and Imricor Medical Systems (ASX: IMR), a pioneer and world-leading developer of MR-compatible products for interventional MR procedures, today announced a new Interventional MR (iMR) lab solution for Philips 1.5T MR. The first commercially available configuration* combines Philips’ 1.5T MRI platform and Imricor's portfolio of iMR systems and consumables, enabling an MR-guided workflow for cardiac intervention, without compromising on MR field strength. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260827693715/en/ Meeting the need for greater tissue insight during cardiac intervention Cardiac arrhythmias affect millions of people worldwide, and catheter ablation is an established and increasingly utilized treatment for many complex cardiac arrhythmias. Yet today, these procedures continue to rely primarily on X-ray fluoroscopy, which provides only
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
